The renal benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RA) are based mainly on preservation of glomerular filtration and a reduction in macroalbuminuria. In controlled studies dulaglutide has shown good metabolic rate and slows the progression of glomerular filtration rate (GFR) loss. We analyzed, the metabolic control, the renal preservation data based on estimated GFR (eGFR) and the relationship of eGFR changes with baseline values at 36 months (M) follow–up. The results shows: glycated hemoglobin was reduced −1.4% at 12M, (p<0.001), fasting blood glucose showed a significant reduction (−30 mg/dL) at 12M (p=0.005), weight showed a 3.6 kg reduction at 12M (p=0.009). GFR did not show a worsening during follow-up: baseline value was 88.10±26.47 ml/min/1.73m2 and remained stable (83.25±29.27 ml/min/1.73m2; p=0.134) at the end of the study. Based on the 36M follow-up results, dulaglutide was shown to be an effective and nephroprotective drug in diabetic patients.